Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion–positive non–small cell lung cancer cells

References

• Chan BA, Hughes BG. 2015. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 4:36–54.4. doi:10.3978/j..2218-6751.2014.05.01.
   PubMed Web of Science ®Google Scholar
• Sgambato A, Casaluce F, Maione P, Gridelli C. 2018. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer Ther. 18:71–80.5. doi:10.1080/14737140.2018.1412260.
   PubMed Web of Science ®Google Scholar
• Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005;16:441–467.6. doi:10.1016/j.cytogfr.2005.05.010.
   PubMed Web of Science ®Google Scholar
• Lin C, Wang S, Xie W, Zheng R, Gan Y, Chang J. 2016. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway. Oncotarget. 7:59236–59244.7. doi:10.18632/oncotarget.10985.
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, Oikawa N, Tsukuda T, Ishii N, Aoki Y. 2011. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 19:679–690.8. doi:10.1016/j.ccr.2011.04.004.
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Perol M, Dziadziuszko R, Rosell R, et al. 2017. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 377:829–838.10. doi:10.1056/NEJMoa1704795.
   PubMed Web of Science ®Google Scholar
• Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H. 2014. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol Cancer Ther. 13:2910–2918.11. doi:10.1158/1535-7163.MCT-14-0274.
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Murayama T, Yoshimura K, Kawakami T, Takahara S, Imai Y, Kuribayashi Y, Nagase K, Goto K, Nishio M, et al. 2017. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol. J Med Invest. 64:317–320.13. doi:10.2152/jmi.64.317.
   PubMed Web of Science ®Google Scholar
• Wells SA Jr., Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, et al. 2012. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 30:134–141.38. doi:10.1200/jco.2011.35.5040.
   PubMed Web of Science ®Google Scholar
• Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, Schoffski P, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS. 2016. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 122:3856–3864.39. doi:10.1002/cncr.30252.
   PubMed Web of Science ®Google Scholar
• Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, et al. 2017. Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry. J Clin Oncol. 35:1403–1410.37. doi:10.1200/JCO.2016.70.9352.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, et al. 2018. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 29:1869–1876.29. doi:10.1093/annonc/mdy137.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, et al. 2018. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 8:836–849.53. doi:10.1158/2159-8290.cd-18-0338.
   PubMed Web of Science ®Google Scholar
• Ackermann CJ, Stock G, Tay R, Dawod M, Gomes F, Califano R. 2019. Targeted therapy for RET-rearranged non-small cell lung cancer: clinical development and future directions. Onco Targets Ther. 12:7857–7864.54. doi:10.2147/ott.s171665.
   PubMed Web of Science ®Google Scholar
• Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, et al. 2014. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 15:1236–1244.30. doi:10.1016/s1470-2045(14)70381-x.
   PubMed Web of Science ®Google Scholar
• Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015;21:1038–1047.15. doi:10.1038/nm.3930.
   PubMed Web of Science ®Google Scholar
• Valentino F, Borra G, Allione P, Rossi L. 2018. Emerging targets in advanced non-small-cell lung cancer. Future Oncol. 14:61–72.20. doi:10.2217/fon-2018-0099.
   PubMed Web of Science ®Google Scholar
• Dolly SO, Collins DC, Sundar R, Popat S, Yap TA. 2017. Advances in the development of molecularly targeted agents in non-small-cell lung cancer. Drugs. 77:813–827.21. doi:10.1007/s40265-017-0732-2.
   PubMed Web of Science ®Google Scholar
• Pillai RN, Ramalingam SS. 2014. Heat shock protein 90 inhibitors in non-small-cell lung cancer. Curr Opin Oncol. 26:159–164.41. doi:10.1097/cco.0000000000000047.
   PubMed Web of Science ®Google Scholar
• Matsubara D, Kanai Y, Ishikawa S, Ohara S, Yoshimoto T, Sakatani T, Oguni S, Tamura T, Kataoka H, Endo S, et al. 2012. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. J Thorac Oncol. 7:1872–1876.42. doi:10.1097/JTO.0b013e3182721ed1.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute, NCI drug dictionary, pemetrexed disodium. [accessed 2019 Jun 27]. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pemetrexed-disodium
   Google Scholar
• Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–392.45. doi:10.1056/NEJMra035536.
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427–1438.47.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration, Label for NDA 021991. [accessed 2019 Jun 27]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021991s001lbl.pdf
   Google Scholar
• Burger MT, Pecchi S, Wagman A, Ni ZJ, Knapp M, Hendrickson T, Atallah G, Pfister K, Zhang Y, Bartulis S, et al. 2011. Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer. ACS Med Chem Lett. 2:774–779.50. doi:10.1021/ml200156t.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute, NCI Drug dictionary, gedatolisib. [accessed 2019 Jun 27]. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/gedatolisib
   Google Scholar
• U.S. Food and Drug Administration, Labels for NDA 022334. [accessed 2019 Jun 27]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022334lbl.pdf
   Google Scholar
• U.S. Food and Drug Administration, Labels for NDA 208716. [accessed 2019 Jun 27]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf
   Google Scholar
• Foucquier J, Guedj M. 2015. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 3:e00149.40. doi:10.1002/prp2.149.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhang S, Chen X, Zheng X, Yao Y, Lu G, Zhou J. 2017. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer. Cancer Lett. 408:130–137.22. doi:10.1016/j.canlet.2017.08.031.
   PubMed Web of Science ®Google Scholar
• Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, et al. 2016. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell. 29:255–269.25. doi:10.1016/j.ccell.2016.02.006.
   PubMed Web of Science ®Google Scholar
• Wood AC, Krytska K, Ryles HT, Infarinato NR, Sano R, Hansel TD, Hart LS, King FJ, Smith TR, Ainscow E, et al. 2017. Dual ALK and CDK4/6 inhibition demonstrates synergy against neuroblastoma. Clin Cancer Res. 23:2856–2868.2. doi:10.1158/1078-0432.CCR-16-1114.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wu Z, Wong G, Pectasides E, Nagaraja A, Stachler M, Zhang H, Chen T, Zhang H, Liu JB, et al. 2017. CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Nat Commun. 8:13897.26. doi:10.1038/ncomms13897.
   Web of Science ®Google Scholar
• Liu M, Xu S, Wang Y, Li Y, Li Y, Zhang H, Liu H, Chen JPD. 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Oncotarget. 2016;7:84951–84964.33. doi:10.18632/oncotarget.13069.
   PubMedGoogle Scholar
• Kim S, Kim TM, Kim DW, Go H, Keam B, Lee SH, Ku JL, Chung DH, Heo DS. 2013. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol. 8:415–422.43. doi:10.1097/JTO.0b013e318283dcc0.
   PubMed Web of Science ®Google Scholar
• Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. 2010. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol. 148:3–15.55. doi:10.1016/j.jbiotec.2010.01.012.
   PubMed Web of Science ®Google Scholar
• Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, Fujimoto-Ouchi K. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res. 2011;17:–5060–5070.19. doi:10.1158/1078-0432.ccr-10-2927.
   PubMedGoogle Scholar
• Zhao L, Au JL, Wientjes MG. Comparison of methods for evaluating drug-drug interaction. Front Biosci (Elite Ed). 2010;2:241–249.36. doi:10.2741/e86.
   PubMedGoogle Scholar